Document is current
Any future updates will be listed below
-
Authors
Sirvén, Milana Bergamino
Fernández-Ortega, Adela
Stradella, Agostina
Morilla, Idoia
Falo, Catalina
Vázquez, Silvia
Castany, Roser
Villanueva, Rafael
Recalde, Sabela
Pérez, Valentí Navarro
Gil-Gil, Miguel
Pernas, Sonia http://orcid.org/0000-0002-1485-5080
- License Information
-
More Information
Article History
Received: 12 September 2019
Accepted: 25 October 2019
First Online: 21 November 2019
Ethics approval and consent to participate
: This study was carried out following relevant guidelines and regulations. This is an observational retrospective study approved by the Ethical Committee from the Institut Català d’Oncologia (ICO). We obtained the written consent from the alive patients to use their data, however most of patients had deceased when the study was conducted, and the Committee considered that it was acceptable to have a verbal consent from them.
: Not applicable.
: Miguel Gil-Gil has received honoraria from Novartis, Pfizer, Pierre-Fabre and Roche and has advisory role to Daiichi-Sankyo, Novartis and Pfizer. Sonia Pernas has received honoraria for talks and travel grants from Roche, and has served on advisory boards for Polyphor. Catalina Falo has received travel from Pfizer. The rest of the authors have no competing interest to disclosure.
